A preconsultation web-based tool to generate an agenda for discussion in diabetes outpatient clinics to improve patient outcomes (DIAT): a feasibility study. by Ukoumunne, OC et al.
A preconsultation web-based tool
to generate an agenda for discussion
in diabetes outpatient clinics to
improve patient outcomes (DIAT):
a feasibility study
Obioha C Ukoumunne,1 Bijay Vaidya,2 Julia Frost,3 Rob Anderson,4
Catherine Argyle,5 Mark Daly,5 Faith Harris-Golesworthy,6 Jim Harris,6
Andy Gibson,3 Wendy Ingram,7 Jon Pinkney,8 Jane Vickery,7 Nicky Britten1
To cite: Ukoumunne OC,
Vaidya B, Frost J, et al. A
preconsultation web-based
tool to generate an agenda
for discussion in diabetes
outpatient clinics to
improve patient outcomes
(DIAT): a feasibility study.
BMJ Open 2017;7:e013519.
doi:10.1136/bmjopen-2016-
013519
▸ Prepublication history and
additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjopen-2016-
013519).
Received 18 July 2016
Revised 12 January 2017
Accepted 10 February 2017
For numbered affiliations see
end of article.
Correspondence to
Dr Obioha C Ukoumunne;
O.C.Ukoumunn@exeter.ac.uk
ABSTRACT
Objective: To test the feasibility of running a
randomised controlled trial of a preconsultation
web-based intervention (Presenting Asking Checking
Expressing (PACE-D)) to improve the quality of care
and clinical outcomes in patients with diabetes.
Design and setting: A feasibility study (with
randomisation) conducted at outpatient diabetes clinics
at two secondary care hospitals in Devon, UK.
Participants: People with diabetes (type 1 and type
2) attending secondary care general diabetes outpatient
clinics.
Intervention: The PACE-D, a web-based tool adapted
for patients with diabetes to use before their
consultation to generate an agenda of topics to discuss
with their diabetologist.
Outcomes: The percentage of eligible patients who
were recruited and the percentage of participants for
whom routine glycosylated haemoglobin (HbA1c) data
(the putative primary outcome) could be extracted from
medical notes and who completed secondary outcome
assessments via questionnaire at follow-up were
reported.
Results: In contrast with the planned recruitment of
120 participants, only 71 participants were randomised
during the 7-month recruitment period. This comprised
18.7% (95% CI 14.9% to 23.0%) of those who were
eligible. Mean (SD) age of the participants was 56.5
(12.4) years and 66.2% had type 1 diabetes. Thirty-
eight patients were randomised to the intervention arm
and 33 to the control arm. HbA1c data were available
for only 73% (95% CI 61% to 83%) of participants at
the 6 months follow-up. The questionnaire-based data
were collected for 66% (95% CI 54% to 77%) of the
participants at 6 months follow-up. Participants
reported that the PACE-D tool was easy to use.
Conclusions: A randomised controlled trial of the
preconsultation web-based intervention as set out in
our current protocol is not feasible without significant
modification to improve recruitment and follow-up of
participants. The study also provides insights into the
feasibility and challenges of conducting complex
intervention trials in everyday clinical practice.
Trial registration: ISRCTN75070242.
INTRODUCTION
Diabetes is a common chronic condition
affecting about 4 million people in the UK
and by 2025 it is estimated that the preva-
lence will rise to over 5 million.1 People with
diabetes are at an increased risk of develop-
ing several serious long-term complications,
such as ischaemic heart disease, stroke,
chronic kidney disease, blindness and ampu-
tations, associated with disability and prema-
ture death as well as a huge economic cost to
the individual and society. Optimal control
of diabetes can prevent or delay the onset of
these complications.2 3
Although diabetes is largely a self-managed
condition, specialist healthcare professionals
have a vital role to play by helping patients to
achieve good diabetes control and to cope
with their illness through expert advice, edu-
cation and support.4 Effective consultations
with healthcare professionals have been
Strengths and limitations of the study
▪ Patients are involved in the development of the
intervention.
▪ The trial is conducted at two hospital sites.
▪ Outcomes are comprised of self-reported patient
data collected via questionnaire and routine gly-
cosylated haemoglobin measurements.
▪ The patients, clinicians and healthcare staff are
not blinded to intervention status.
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shown to enhance patient empowerment, promote
positive behaviour change and improve diabetes
outcomes.5–7 However, consultations with healthcare
professionals tend to be infrequent and time limited,
and patients often feel unable to discuss their concerns.8
Therefore, interventions that enable patients to discuss
their concerns may be advantageous in encouraging
better self-management.
Cegala and colleagues9 have previously suggested that
communication skills training for patients can enhance
their participation in the medical consultation. They
have proposed the Presenting Asking Checking
Expressing (PACE) system for patients to develop effect-
ive communication; this involves patients presenting
detailed information about how they are feeling, asking
questions if desired information is not provided, checking
understanding of information that is given to them and
expressing any concerns about the recommended treat-
ment.10 The PACE system was modiﬁed speciﬁcally for
diabetes to produce a web-based tool (designated
PACE-diabetes or PACE-D), designed to be completed
by a patient immediately before a clinic appointment
with a diabetes specialist to identify the issues that they
would wish to discuss in the clinic (ie, their ‘agenda’).
Web-based educational interventions have recently been
evaluated for patients with diabetes.11 12
Here, we report results of a randomised controlled
trial that we carried out to assess the feasibility of and
obtain the necessary information for planning a future
deﬁnitive trial of this web-based preconsultation inter-
vention (PACE-D) to improve the care quality and clin-
ical outcomes of patients with diabetes. Findings from
qualitative work carried out alongside the trial (with
the aims of exploring patient and public involvement
(PPI) in trial processes, patient experience and rele-
vant organisational factors) are reported in separate
papers.
SETTING, SUBJECTS AND METHODS
This feasibility study used a pragmatic parallel group
randomised controlled trial design (trial registration
number: ISRCTN75070242) with the overall aim of
establishing the feasibility of a deﬁnitive superiority trial
of the PACE-D agenda setting tool.13
Study setting and recruitment
Patients with diabetes were recruited from two sites
(Macleod Diabetes and Endocrine Centre at the Royal
Devon & Exeter Hospital, Exeter and the Medical
Outpatients Department at Derriford Hospital,
Plymouth) in Devon, South West England. Eligible
patients met all of the following criteria: aged 18 years
or over; with type 1 or type 2 diabetes mellitus; due to
attend for a hospital outpatient appointment with a dia-
betologist and had sufﬁcient written and spoken English
to complete the study assessments. Women with gesta-
tional diabetes and patients receiving insulin pump
therapy were excluded as these patients are seen in spe-
cialised clinics.
Potentially eligible patients who were due to attend a
general diabetes clinic appointment were identiﬁed
from clinic lists by healthcare assistants who had been
specially trained for the study. Patients who were willing
to be contacted were sent an information sheet about
the trial and were contacted by phone by the healthcare
assistant no less than a week later to conﬁrm eligibility
and discuss the study. Patients who wanted to take part
in the study were then sent a consent form and baseline
questionnaire. On receipt of the signed consent form,
the patient was randomised.
Randomisation
Participants were randomised in a 1:1 ratio to the inter-
vention or control arms using a computer-generated
random allocation sequence prepared by the Peninsula
Clinical Trials Unit at Plymouth University (PenCTU).
An automated web-based system was used to conceal the
allocation. Randomisation was stratiﬁed by clinic session
using randomly permuted block sizes in a non-systematic
sequence. Allocation occurred on receipt of the patient’s
completed consent form. Following allocation, the hos-
pital informed the patient, via a standard letter, of the
time of their clinic appointment. Participants in
the intervention arm were asked to attend 30 min
before the start of their appointment to ensure sufﬁcient
time to complete the PACE-D tool. For both trial arms,
if the baseline questionnaire had not been returned to
the CTU before the clinic appointment, the participant
was asked to complete it in clinic, prior to the consult-
ation (and prior to the PACE-D for those in the inter-
vention arm).
Interventions
The PACE-D intervention is a web-based tool used by
the patient before their consultation to generate an
agenda of topics to discuss with their diabetologist. It is
based on the PACE tool developed by Cegala and collea-
gues9 and was modiﬁed for use with patients with dia-
betes by the DIAT study team and PPI representatives
(ie, people with experience of living with diabetes). A
review of the literature had identiﬁed several candidate
interventions, which were discussed and tested by the
study team. PACE had been shown to enable patient
communication skills to move beyond noting concerns,
allowing the patient to take an active role in shaping
the dynamic of the physician–patient relationship and
the ﬂow of information.14 The PACE curricula were tai-
lored to diabetes speciﬁcally, with input from the
two PPI coauthors who shaped the development of
the intervention with the web designers at PenCTU,
using easy-to-access information from the Diabetes UK
website (https://www.diabetes.org.uk/Guide-to-diabetes/?
gclid=CITP94CthdACFQEA0wodVjMJBQ) and their
experiential knowledge. A working group of eight people
with diabetes was convened by the PPI facilitator. In a
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3-hour workshop, this group tested and provided feed-
back on this early iteration of the intervention. The inter-
vention was ﬁne-tuned using an iterative process.
The PACE-D consists of several open and closed ques-
tions, prompts and a list of potential concerns the
patient might have (eg, depression). A healthcare assist-
ant, trained to facilitate the intervention, was on hand to
provide as much help to the patients as required, but
without inﬂuencing their choices, so that they could
go through the PACE-D questions and identify the
problems and topics that they wished to discuss in
their consultation. After completion of the PACE-D
(which takes ∼20 min), a printed personalised consult-
ation agenda was generated for the patient to take into
the consultation. The following documents are included
as online supplementary material with this paper: the
text used in the PACE intervention; the ofﬂine version
of the PACE-D intervention and an example of an
agenda that was generated for a study patient using the
PACE-D.
Patients randomised to the control arm received their
standard outpatient appointment with a diabetologist.
Data collection/measures
Data were collected at baseline, 3 and 6 months compris-
ing results of routine measurement of glycaemic control
extracted from patient records and several patient-
reported measures sent to participants with instructions
for completion and a prepaid return envelope. We
brieﬂy describe the patient-reported measures. Further
details are presented in the protocol paper.13
Glycaemic control, the putative primary outcome for
the deﬁnitive trial of the PACE-D tool, was quantiﬁed
using glycosylated haemoglobin (HbA1c) retrospectively
obtained from participants’ medical records. These data
were therefore obtained opportunistically from routine
measurements the timing of which was unconnected to
the aims of the study. To be used in this study at a given
wave, the HbA1c level needed to be measured within
4 weeks of the intended assessment date.
The Audit of Diabetes-Dependent Quality of Life-19
(ADDQoL) measures the patient’s perception of the
impact of diabetes on their quality of life weighted by its
importance to the individual.15 The mean impact score
(possible scoring range from −9 to +3) across 19
domains (eg, working life, holidays, physical appearance,
etc) was analysed and reported here. Higher scores indi-
cate a more positive state.
The Diabetes Empowerment Scale-short form (DES) mea-
sures diabetes-related psychosocial self-efﬁcacy.16 17 An
overall score for DES (possible range 1–5) is calculated
by taking the mean of the eight constituent items, with
higher scores indicating greater self-efﬁcacy.
The Diabetes Self-care Activity self-report questionnaire is
a measure of diabetes self-management which includes
ﬁve aspects (activities) of the diabetes regimen: 18
general diet, speciﬁc diet, exercise, blood glucose testing
and foot care. The overall score (possible scoring range
0–7) for each activity is based on the number of days in
the past week that the activity was undertaken.
The Diabetes Treatment Satisfaction Questionnaire—Status
(DTSQ(S)) measure and change (DTSQ(C)) versions
were developed to measure patient satisfaction with dia-
betes treatment.19 The total score for the DTSQ(S)
ranges from a possible 0–36 with higher scores indicat-
ing greater satisfaction. The DTSQ change version
(DTSQ(C)) contains the same items, but asks patients to
consider their satisfaction with current treatment com-
pared with their previous treatment.20 The total score
ranges from a possible score −18 to 18. Both versions of
the DTSQ were used in order to capture initial percep-
tions and any change at follow-up.
The Patient Enablement Instrument (PEI) measures
patient enablement after a consultation with a phys-
ician.21 The total score ranges from 0 to 12. We used the
modiﬁed version of Haughney et al,22 in which the
opening statement captures perspectives on treatment
speciﬁcally. Higher scores indicate greater enablement.
Patient Report of Communication. Developed to measure
communication in conjunction with the PACE tool; this
instrument comprises 11 questions about perceived com-
munication, with two items for each of the four PACE
skills, two additional items for the patient’s ability to
state their preferences and a global item about the con-
sultation.14 It uses a 5-point Likert scale format that cap-
tures aspects of doctor–patient communication as never
(1), not very often (2), sometimes (3), usually (4) and
always (5). The total score was calculated as the sum
over the individual items with higher scores indicating
better communication.
The EuroQoL (EQ-5D-5L) was used to measure generic
health-related quality of life. It deﬁnes health in terms
of: mobility, self-care, usual activities, pain/discomfort
and anxiety/depression and uses a 3-point Likert scale
(no problem, some problem, extreme problem).23
However, this instrument has also been found to suffer
from ceiling effects, and a ﬁve-level version has been
developed (EQ-5D-5L), which uses a ﬁve-point Likert
scale (no problem, slight problem, moderate problem,
severe problem and extreme problem) and has demon-
strated increased reliability and sensitivity.24
The Client Services Receipt Inventory was used to collect
cost-related and service use-related information for trial
participants.25 However, as this paper focuses primarily
on trial feasibility and assessment of clinical outcomes,
we do not report the service use and cost data in this
paper (but they are available from the authors).
Other outcomes. Participants were asked to document
their current medication at each time point, as well as
the number and type of contacts with primary and sec-
ondary care practitioners during the study. Finally, those
in the intervention arm were also asked at 6 months
about their experience of using the PACE-D tool and
the utility of producing their agenda.
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Blinding
It was not possible to blind the participating patients,
the consulting diabetologists or the healthcare assistants
due to the nature of the intervention which results in
the generation of a consultation agenda.
Sample size
The study aimed to recruit 120 patients in total. This is
large enough to estimate the percentage that is lost to
follow-up at 3 and 6 months with a margin of error no
greater than ±9.3% based on the 95% CI width.
Assuming that at least 60 patients provide follow-up data,
this is large enough to estimate the SD of the continu-
ous outcome measures to within 22% of their true value
based on the upper limit of the 95% CI.
Statistical analysis
The main objectives of this trial were to afﬁrm aspects of
the feasibility of a deﬁnitive trial and estimate parameters
for planning recruitment and calculating the sample size
for such a study. The percentage of eligible patients who
were recruited, the percentage of participants for whom
HbA1c data could be extracted from medical notes and
the percentage of participants that completed outcome
assessments at follow-up are reported with 95% CIs.
Characteristics of study participants (by trial arm
status) and eligible non-participants are summarised
using means and SDs for continuous variables and
numbers and percentages for categorical variables. The
SDs of the outcome measures (all continuous) are
reported with 95% CIs for each trial arm at each of the
3 and 6 month follow-ups.
In ancillary analyses, we used the intention-to-treat
principle to compare trial arms with respect to the study
outcomes (all continuous) using the t-test for crude esti-
mates of the mean difference and linear regression for
estimates adjusted for study site, time since diagnosis
and the baseline score for the measure. Ninety-ﬁve per
cent CIs for the adjusted mean difference are reported,
but no p values as this is a feasibility study.
RESULTS
The participant ﬂow through the trial is summarised in
ﬁgure 1. Recruitment took place between 24 June 2013
and 31 December 2013. As shown in ﬁgure 2, the
recruitment was slow to start and generally lower than
anticipated particularly in the latter months. Efforts
were made to streamline the recruitment process includ-
ing the following protocol changes: adding an option
for interested potential participants to contact the
screening team directly rather than awaiting a call;
getting a healthcare assistant rather than a research
nurse to check if a participant is still willing to partici-
pate when they attend the outpatient appointment and
reducing the time between sending the initial invitation
letter and the telephone call made to conﬁrm eligibility
and discuss the study.
Three hundred and ninety-ﬁve patients with diabetes
on the waiting list for appointment in the general dia-
betes outpatients clinics were screened for eligibility by
reviewing their case records; 380 of these were eligible
for the trial of whom 71 were recruited, giving a partici-
pation percentage of 18.0% (95% CI 14.3% to 22.1%)
out of those who were screened and 18.7% (95% CI
14.9% to 23.0%) out of those who were eligible. The
number recruited was 59 patients fewer than targeted.
Participation was slightly higher in Exeter than
Plymouth (24.8% of those who were eligible vs 15.8%).
Participants were similar to eligible non-participants with
respect to mean (SD) age at registration (56.5 (12.4)
versus 51.3 (16.1)), type 1 (as opposed to type 2) dia-
betes status (66.2% vs 60.5%) and whether attending for
a new appointment (4.2% vs 8.1%).
Thirty-eight participants were randomised to the inter-
vention arm and 33 to the control arm; the baseline
characteristics are summarised by trial arm status in
table 1. The 3-month follow-up questionnaires were
received between 25 September 2013 and 8 May 2014
and the 6-month follow-up questionnaires between 23
December 2013 and 15 August 2014. The number of par-
ticipants for whom HbA1c data could be extracted and
who provided questionnaire data at each wave is reported
in table 2. There was a large amount of missing data on
HbA1c with only 73% (95% CI 61 to 83%) having a
routine assessment within 4 weeks of the scheduled
6-month follow-up date. Even fewer (66%; 95% CI 54 to
77%) provided questionnaire data at that wave.
Table 2 summarises the comparison of the study out-
comes between the intervention and control arms at 3
and 6 months. These are ancillary analyses, as the
primary aim of this feasibility study is to estimate the para-
meters required for planning a deﬁnitive trial. Reﬂecting
the small sample size, the CIs for the differences between
the trial arms were too wide to be conﬁdent of a deﬁnite
beneﬁt or harm related to the intervention or to rule out
the possibility of beneﬁts or harms. Table 3 reports the
SD of the outcomes at each of the 3 and 6 month follow-
ups by trial arm status with 95% CIs. Table 4 summarises
the responses to the EuroQoL items.
Thirty of the 38 participants (79%; 95% CI 63% to
90%) in the intervention arm completed the full
PACE-D questionnaire and another patient completed
only the ﬁrst of the six parts of the instrument.
The median (IQR; range) time taken to complete the
PACE-D was 7.1 (4.2–10.5; 2.1–36.3) minutes. Of the
intervention participants who responded to questions on
how they experienced the PACE-D, 90% ((19/21); 95%
CI 70% to 99%) found it to be useful; 84% ((16/19);
95% CI 60% to 97%) found it convenient and easy to
use; 81% ((17/21); 95% CI 58% to 95%) thought it
helped them think about issues related to their care;
81% ((17/21); 95% CI 58% to 95%) thought it helped
them think about their experience of diabetes; 81%
((17/21); 95% CI 58% to 95%) said that it did not
increase any stress associated with their appointment
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and 45% ((9/20); 95% CI 23% to 68%) said that it did
change the way the doctor dealt with them. When com-
paring the length of the consultation, there was little evi-
dence of a difference between the intervention and
control arms (mean (SD): 20.2 (12.1) versus 21.8 (8.4)
minutes; mean difference: -1.6; 95% CI −8.3 to 5.1;
p=0.64).
DISCUSSION
This feasibility study experienced difﬁculties in
recruiting and following up trial participants. Therefore,
despite participant reports that the intervention
(PACE-D) was acceptable to a majority of patients and
was not associated with an increase in the length of the
clinic consultation, it would not be feasible to run a
deﬁnitive randomised controlled trial using the current
protocol without further development.
This study provides insights into the challenges of con-
ducting a complex trial in everyday clinical practice as
shown by the fact that we were able to recruit less than
one in ﬁve eligible patients into this study. As healthcare
team members are often faced with severe time pres-
sures at their work, a key to successful implementation
Figure 1 CONSORT diagram. aThe recruitment process was amended during the recruitment phase, and the denominator for
the reasons that patients were not randomised varies accordingly. bThere was no HbA1c result within the time window recorded
on the participating hospital’s laboratory database.
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of a new care delivery intervention is to ﬁt in the inter-
vention with existing workﬂows and cause minimal dis-
ruptions on current workﬂow practices.26 In our study,
the process of recruitment, the logistics of the interven-
tion and the extent of data collection in terms of
outcome measures appeared too complex, and seemed
to have put an extra demand on patients and healthcare
professionals impacting on recruitment and on data
completeness. Data on HbA1c, the intended primary
outcome of the deﬁnitive trial, were obtainable for only
Figure 2 Final recruitment
graph (24 June 2013 to 31
December 2013).
Table 1 Baseline characteristics by trial arm status
Characteristics Intervention N=38 Control N=33
Female patient, % 50 45
Age at registration, mean (SD) 55.3 (12.4) 57.8 (12.6)
White, % 96 93
Height in cm, mean (SD) 167 (7) 171 (8)
Weight in kg, mean (SD) 95 (27) 93 (27)
Time since diagnosis
<5 years, % 19 15
5–10 years, % 23 8
10–20 years, % 27 42
20 years or more, % 31 35
Diagnosed by
GP, % 69 76
Consultant, % 31 24
Diabetes status
Type I, % 61 73
Type II, % 39 27
HbA1c, mean (SD) 70.7 (17.1) 68.2 (14.9)
ADDQoL—average weighted impact score, mean (SD) −1.6 (1.5) −2.8 (2.2)
Diabetes Empowerment Scale—short form, mean (SD) 3.4 (0.6) 3.6 (0.6)
DSCAQ—General Diet score, mean (SD) 4.7 (2.1) 4.5 (2.3)
DSCAQ—Specific Diet score, mean (SD) 4.2 (1.6) 4.4 (1.9)
DSCAQ—Exercise score, mean (SD) 3.3 (2.4) 3.0 (2.7)
DSCAQ—Blood Glucose Testing score, mean (SD) 4.9 (2.4) 5.9 (1.9)
DSCAQ—Foot Care score, mean (SD) 2.9 (2.2) 2.8 (2.4)
Diabetes Treatment Satisfaction Questionnaire score, mean (SD) 27.7 (6.8) 28.7 (6.0)
Patient Enablement Instrument, mean (SD) 8.4 (4.0) 7.2 (3.8)
Patient Report of Communication Behaviour, mean (SD) 38.7 (8.0) 39.3 (8.7)
Sample size ranges from 23 to 38 in the intervention arm and from 24 to 33 in the control arm.
ADDQoL, Audit of Diabetes-Dependent Quality of Life; GP, general practitioner; HbA1c, glycosylated haemoglobin.
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86% of participants at baseline, 45% at the 3 month
follow-up and 73% at the 6 month follow-up; this may
reﬂect the frequency of HbA1c measurements that
patients with diabetes undergo in the routine clinical
practice. If such data are to be obtained in a deﬁnitive
trial, their collection needs to be built into the research
or the timings for inclusion of routine measurement of
this outcome need to be more ﬂexibly and realistically
Table 2 Three and 6-month outcome results by trial arm
Outcome and time point
Intervention Control Intervention—control
N mean (SD) N mean (SD)
mean
diff.
adj. mean
diff. (95% CI)
3 months
HbA1c 16 67.4 (17.6) 16 66.6 (10.4) 0.8 0.4 (−11.9 to 12.7)
ADDQoL—average weighted impact score 25 −1.4 (1.4) 26 −2.6 (2.0) 1.2 0.3 (−0.6 to 1.1)
Diabetes Empowerment Scale—short form 22 3.6 (0.5) 25 3.6 (0.7) 0.03 0.01 (−0.4 to 0.4)
DSCAQ—General Diet score 24 4.7 (2.3) 24 4.5 (2.3) 0.2 0.05 (−1.1 to 1.2)
DSCAQ—Specific Diet score 25 3.9 (2.1) 25 4.1 (1.6) −0.2 0.008 (−0.9 to 0.9)
DSCAQ—Exercise score 25 3.2 (2.2) 24 2.8 (2.4) 0.4 −0.2 (−1.3 to 1.0)
DSCAQ—Blood Glucose Testing score 23 5.2 (2.0) 24 6.1 (1.7) −0.8 −0.03 (−1.2 to 1.2)
DSCAQ—Foot Care score 25 3.6 (2.3) 24 3.3 (2.4) 0.3 0.2 (−0.8 to 1.1)
Diabetes Treatment Satisfaction Questionnaire score 24 28.4 (6.0) 25 28.6 (6.3) −0.2 0.7 (−2.8 to 4.2)
Diabetes Treatment Satisfaction Questionnaire
change score
24 4.8 (9.9) 22 4.4 (8.3) 0.4 0.1 (−6.8 to 7.0)
Patient Enablement Instrument 23 8.1 (3.6) 24 7.5 (4.1) 0.6 −0.5 (−2.6 to 1.6)
Patient Report of Communication Behaviour 24 42.9 (6.0) 25 39.3 (6.8) 3.6 2.1 (−1.1 to 5.2)
6 months
HbA1c 26 71.6 (16.8) 26 71.1 (20.4) 0.5 −3.4 (−13.1 to 6.3)
ADDQoL—average weighted impact score 23 −1.4 (1.6) 24 −2.2 (1.9) 0.8 −0.1 (−1.0 to 0.7)
Diabetes Empowerment Scale—short form 23 3.7 (0.5) 24 3.7 (0.6) −0.04 −0.008 (−0.4 to 0.4)
DSCAQ—General Diet score 23 4.5 (2.0) 24 5.1 (2.4) −0.6 −0.9 (−2.1 to 0.3)
DSCAQ—Specific Diet score 23 3.8 (1.2) 24 4.4 (1.2) −0.7 −0.3 (−1.0 to 0.3)
DSCAQ—Exercise score 23 3.5 (2.3) 20 2.4 (2.4) 1.1 1.4 (0.09 to 2.6)
DSCAQ—Blood Glucose Testing score 23 5.2 (2.3) 23 6.4 (1.4) −1.2 0.08 (−1.1 to 1.2)
DSCAQ—Foot Care score 23 3.7 (2.2) 23 3.3 (2.7) 0.4 0.4 (−0.9 to 1.6)
Diabetes Treatment Satisfaction Questionnaire score 22 30 (7.2) 21 29.0 (6.4) 1.0 0.7 (−3.5 to 5.0)
Diabetes Treatment Satisfaction Questionnaire
change score
21 6.6 (11.1) 22 4.4 (11.9) 2.2 0.9 (−7.3 to 9.2)
Patient Enablement Instrument 19 9.8 (3.3) 22 7.2 (3.9) 2.6 2.5 (0.8 to 4.1)
Patient Report of Communication Behaviour 23 42.1 (7.3) 24 41.7 (7.1) 0.4 2.0 (−3.0 to 7.1)
ADDQoL, Audit of Diabetes-Dependent Quality of Life; HbA1c, glycosylated haemoglobin.
Table 3 SD (95% CI) of outcome measures at 3 and 6 month follow-ups by trial arm status
Measure
3 month follow-up 6 month follow-up
Intervention Control Intervention Control
HbA1c 17.6 (13.0 to 27.2) 10.4 (7.7 to 16.1) 16.8 (13.2 to 23.2) 20.4 (16.0 to 28.2)
ADDQoL—average weighted impact score 1.4 (1.1 to 1.9) 2.0 (1.6 to 2.8) 1.6 (1.2 to 2.3) 1.9 (1.5 to 2.7)
Diabetes Empowerment Scale—short form 0.5 (0.3 to 0.7) 0.7 (0.5 to 1.0) 0.5 (0.4 to 0.7) 0.6 (0.5 to 0.8)
DSCAQ—General Diet score 2.3 (1.8 to 3.2) 2.3 (1.8 to 3.2) 2.0 (1.6 to 2.8) 2.4 (1.9 to 3.4)
DSCAQ—Specific Diet score 2.1 (1.6 to 2.9) 1.6 (1.2 to 2.2) 1.2 (0.9 to 1.7) 1.2 (0.9 to 1.7)
DSCAQ—Exercise score 2.2 (1.7 to 3.1) 2.4 (1.9 to 3.4) 2.3 (1.8 to 3.3) 2.4 (1.8 to 3.5)
DSCAQ—Blood Glucose Testing score 2.0 (1.5 to 2.8) 1.7 (1.3 to 2.4) 2.3 (1.8 to 3.3) 1.4 (1.1 to 2.0)
DSCAQ—Foot Care score 2.3 (1.8 to 3.2) 2.4 (1.9 to 3.4) 2.2 (1.7 to 3.1) 2.7 (2.1 to 3.8)
Diabetes Treatment Satisfaction
Questionnaire score
6.0 (4.7 to 8.4) 6.3 (4.9 to 8.8) 7.2 (5.5 to 10.3) 6.4 (4.9 to 9.2)
Diabetes Treatment Satisfaction
Questionnaire change score
9.9 (7.7 to 13.9) 8.3 (6.4 to 11.9) 11.1 (8.5 to 16.0) 11.9 (9.2 to 17.0)
Patient Enablement Instrument 3.6 (2.8 to 5.1) 4.1 (3.2 to 5.8) 3.3 (2.5 to 4.9) 3.9 (3.0 to 5.6)
Patient Report of Communication Behaviour 6.0 (4.7 to 8.4) 6.8 (5.3 to 9.5) 7.3 (5.6 to 10.3) 7.1 (5.5 to 10.0)
ADDQoL, Audit of Diabetes-Dependent Quality of Life; HbA1c, glycosylated haemoglobin.
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deﬁned. Data accrual for the questionnaire-based sec-
ondary outcome measures was, however, also similarly
inadequate. For a future deﬁnitive randomised con-
trolled trial, major modiﬁcations to the protocol will be
required so that these processes are made much simpler
and more seamless to improve recruitment and data
collection.
The majority of patients who completed the PACE-D
found the intervention acceptable, easy to use and
helped them think about issues related to their care;
nearly half of them reported that it changed the way the
doctor dealt with them. We recruited people with known
diabetes, many of whom had attended the clinics before
and some of whom know the clinic staff quite well.
Our ﬁndings suggest that even for this group, for whom
it is more likely that their major questions had already
been addressed, the PACE-D tool is potentially useful.
We would speculate that newly diagnosed diabetes
patients may beneﬁt to a still greater degree.
Our ﬁndings are consistent with those of a previous
study which showed that an online communication tool
based on the PACE system is highly acceptable to
patients with cancer.27 The time and input from health-
care assistants that patients required for completing the
PACE-D tool in our study was highly variable, suggesting
some patients may be more comfortable using the inter-
vention than others. There was a general perception
among consultants that PACE-D would increase the con-
sultation time. However, the length of the consultation
was found to be similar in the intervention and control
arms of the study. This study also showed that, with
appropriate training, this intervention could be deli-
vered by healthcare assistants, and the scarce resources
of diabetes specialist nurses are unnecessary for its
delivery.
A strength of this study is the participation of PPI
representatives (16 altogether) at all stages of the study,
including proposing the research question, study
design, intervention development, training of healthcare
assistants, analysis of qualitative data, steering committee
membership and preparation of the protocol paper.13
This study shows how PPI representatives can make a
Table 4 Responses to EuroQol items at 3 and 6 months by trial arm
EuroQol item
3 months 6 months
Intervention Control Intervention Control
n (%) n (%) n (%) n (%)
Mobility
No problems 15 (60) 10 (40) 13 (57) 11 (46)
Slight problems 5 (20) 2 (8) 4 (17) 3 (13)
Moderate problems 4 (16) 9 (36) 4 (17) 6 (25)
Severe problems 1 (4) 2 (8) 2 (9) 3 (13)
Unable to/extreme 0 (0) 2 (8) 0 (0) 1 (4)
Self-care
No problems 21 (84) 13 (50) 19 (83) 14 (58)
Slight problems 2 (8) 6 (23) 1 (4) 3 (13)
Moderate problems 1 (4) 5 (19) 3 (13) 5 (21)
Severe problems 1 (4) 1 (4) 0 (0) 1 (4)
Unable to/extreme 0 (0) 1 (4) 0 (0) 1 (4)
Usual activities
No problems 18 (72) 11 (42) 12 (55) 11 (46)
Slight problems 2 (8) 5 (19) 4 (18) 5 (21)
Moderate problems 3 (12) 7 (27) 4 (18) 4 (17)
Severe problems 1 (4) 2 (8) 2 (9) 4 (17)
Unable to/extreme 1 (4) 1 (4) 0 (0) 0 (0)
Pain/discomfort
No problems 10 (40) 6 (24) 10 (43) 9 (38)
Slight problems 10 (40) 4 (16) 8 (35) 6 (25)
Moderate problems 2 (8) 11 (44) 3 (13) 6 (25)
Severe problems 3 (12) 3 (12) 1 (4) 2 (8)
Unable to/extreme 0 (0) 1 (4) 1 (4) 1 (4)
Anxiety/depression
No problems 18 (72) 12 (46) 13 (57) 14 (58)
Slight problems 5 (20) 6 (23) 8 (35) 4 (17)
Moderate problems 1 (4) 5 (19) 2 (9) 3 (13)
Severe problems 1 (4) 3 (12) 0 (0) 2 (8)
Unable to/extreme 0 (0) 0 (0) 0 (0) 1 (4)
N=25 in the intervention arm at 3 months; 25–26 in the control arm at 3 months; 22–23 in the intervention arm at 6 months and 24 in the
control arm at 6 months.
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valuable contribution to study design and data analysis,
and how PPI representatives and healthcare profes-
sionals can work together in the design and implemen-
tation of a clinic trial. This will be reported more fully in
another paper.
The study examined several outcomes. Although the
Patient Report of Communication measure is designed
to capture the impact of the PACE-D, it is questionable
whether the other patient-centred outcomes and gly-
caemic control do. Lack of a theoretical basis for an
intervention effect also applies to other potential clinical
outcomes not measured here that are relevant to dia-
betes control, such as lipid levels and blood pressure.
The available literature on the pathway between commu-
nication and health outcomes28 29 may provide a frame-
work for choosing the appropriate measures for
evaluating the PACE-D intervention in a deﬁnitive study.
CONCLUSION
The study suggests that the modiﬁed version of the
PACE tool was acceptable to patients and helped them
to articulate their agendas before an outpatient clinic
appointment. It also suggests that this intervention,
despite the initial apprehensions of clinical staff, did not
lead to longer consultations. Although the study demon-
strated that the randomised controlled trial of a web-
based preconsultation intervention tool as set out in our
original protocol is not feasible, it provides insights into
the role of agenda forms in medical consultations. It
also provides insights into the difﬁculties of conducting
health services research in clinical settings and the need
to have proportionate recruitment procedures for non-
clinical interventions. Finally it, adds to our learning
about the involvement of PPI representatives in trials of
complex interventions.
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